Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35688173

Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2022 Jul
First author
Motzer RJ

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jul;23(7):e319. doi: 10.1016/S1470-2045(22)00346-1.
    note
    Source null
    related pmid
    35772462
    relationship
    Erratum in
  2. citation
    Lancet Oncol. 2022 Sep;23(9):e404. doi: 10.1016/S1470-2045(22)00511-3.
    note
    Source null
    related pmid
    36055306
    relationship
    Erratum in

Authors and identifiers

  1. name
    Motzer RJ
    type
    Author
  2. name
    Powles T
    type
    Author
  3. name
    Burotto M
    type
    Author
  4. name
    Escudier B
    type
    Author
  5. name
    Bourlon MT
    type
    Author
  6. name
    Shah AY
    type
    Author
  7. name
    Suárez C
    type
    Author
  8. name
    Hamzaj A
    type
    Author
  9. name
    Porta C
    type
    Author
  10. name
    Hocking CM
    type
    Author
  11. name
    Kessler ER
    type
    Author
  12. name
    Gurney H
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Motzer RJ
    type
    Author
  2. name
    Powles T
    type
    Author
  3. name
    Burotto M
    type
    Author
  4. name
    Escudier B
    type
    Author
  5. name
    Bourlon MT
    type
    Author
  6. name
    Shah AY
    type
    Author
  7. name
    Suárez C
    type
    Author
  8. name
    Hamzaj A
    type
    Author
  9. name
    Porta C
    type
    Author
  10. name
    Hocking CM
    type
    Author
  11. name
    Kessler ER
    type
    Author
  12. name
    Gurney H
    type
    Author
bibliography ids
  1. nci-bib-d9db8a19c20ae01490574410
book metadata
content sha256
0214007de1ff2808f6d4b64022a9988a80f3f4f3f1b8ae8ec85a0842bcd3405a
document type
citation
dois
  1. 10.1016/S1470-2045(22)00290-X
electronic publication date
display
2022 Jun 7
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35688173
immutable id
pubmed:35688173@0214007de1ff2808f6d4b64022a9988a80f3f4f3f1b8ae8ec85a0842bcd3405a
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
888-898
volume
23
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2022 Jul;23(7):e319. doi: 10.1016/S1470-2045(22)00346-1.
    note
    Source null
    related pmid
    35772462
    relationship
    Erratum in
  2. citation
    Lancet Oncol. 2022 Sep;23(9):e404. doi: 10.1016/S1470-2045(22)00511-3.
    note
    Source null
    related pmid
    36055306
    relationship
    Erratum in
outcomes validated
false
pmid
35688173
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
6c20686005e5d71edf8f28ff64db038755c6bf66ffc526e5bdb52b941a7099e8
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Jul
precision
month
year
2022
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
  5. Research Support, N.I.H., Extramural
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35688173/
title
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice